Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently accepted at: Journal of Participatory Medicine

Date Submitted: Aug 27, 2026
Open Peer Review Period: Aug 31, 2026 - Oct 23, 2026
Date Accepted: Nov 16, 2026
(closed for review but you can still tweet)

This paper has been accepted and is currently in production.

It will appear shortly on 10.2196/110652

The final accepted version (not copyedited yet) is in this tab.

A Patient’s Perspective on Self-Directed Investigation and Management of Long COVID

  • Stephen Merryman

ABSTRACT

I developed long COVID after a SARS-CoV-2 infection in April 2023 and spent nearly 3 years largely housebound, and periodically bedbound, with post-exertional malaise, fatigue, cognitive impairment, muscle twitching, and chest pain. Over that period, I consulted 2 primary care physicians, 7 specialists, and 2 long COVID clinics, and enrolled in 1 clinical trial. Every clinician I met was willing to help, and none had treatments to offer, because no established protocol for treating the underlying condition existed. I eventually concluded that if my long COVID was going to be investigated, I would have to be the prime investigator. This article describes what that looked like from the inside. How I built a personal differential diagnosis out of home-designed tests, selectively ordered laboratory work, and used my own consumer genetic data compared against two unaffected relatives. I describe how I used artificial intelligence tools as teaching aids and built software to automate literature surveillance while cognitively impaired. I further describe how I decided what level of evidence was good enough to act on - when waiting for certainty carried its own risk. And finally, I describe how I tried to keep my self-directed interventions safe. The primary focus of my final 5-month tracking window, January to May 2026, was to observe and document the relationship between a primarily endothelium-targeted intervention and lab markers of endothelial activation, secondary markers of neural overexcitation, and self-ratings of fatigue and function. Over that window, Factor VIII lab values, my measure for endothelial activation, fell from 225 to 117 IU/dL (reference range: 56-140). Plasma glutamic acid, my marker of neural excitation, stayed elevated through my tracking window, though subsequently declined (glutamic acid fell from 242.4 in November 2025 to 232.8 in May 2026 to 164 umol/L in August 2026; reference range: 18.1 – 155.9). My functional capacity score, my marker for fatigue, increased from 4.52 in April 2024 (indicating moderate-mild impairment) to 5.59 in May 2026, indicating mild-to-no impairment.


 Citation

Please cite as:

Merryman S

A Patient’s Perspective on Self-Directed Investigation and Management of Long COVID

Journal of Participatory Medicine. 16/11/2026:110652 (forthcoming/in press)

DOI: 10.2196/110652

URL: https://preprints.jmir.org/preprint/110652

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.